Predicted protein targets (top 13)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CNR2 | P34972 | 8/20 | 0.52 |
| ▸ | CNR1 | P21554 | 7/20 | 0.52 |
| ▸ | HDAC6 | Q9UBN7 | 1/20 | 0.47 |
| ▸ | PDE10A | Q9Y233 | 1/20 | 0.45 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.45 |
| ▸ | CYP2C19 | P33261 | 1/20 | 0.45 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.45 |
| ▸ | LMNA | P02545 | 1/20 | 0.44 |
| ▸ | POLB | P06746 | 1/20 | 0.44 |
| ▸ | RXFP1 | Q9HBX9 | 1/20 | 0.44 |
| ▸ | SMN1; SMN2 | Q16637 | 2/20 | 0.43 |
| ▸ | HTT | P42858 | 1/20 | 0.43 |
| ▸ | WDR5 | P61964 | 1/20 | 0.42 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL2736842 | 0.92 | CNR2 (0.61) | CNR2CNR1HDAC6PDE10AKMT2A | |
| SCHEMBL2736835 | 0.90 | CNR2 (0.47) | CNR2CNR1PDE10ALMNAPOLB | |
| SCHEMBL2736824 | 0.89 | PDE10A (0.55) | CNR2CNR1PDE10ALMNASMN1; SMN2 | |
| SCHEMBL2736871 | 0.88 | CNR2 (0.46) | CNR2CNR1PDE10ACYP1A2CYP2C19 | |
| SCHEMBL2736820 | 0.87 | CNR1 (0.50) | CNR2CNR1HDAC6PDE10ACYP1A2 | |
| SCHEMBL2736810 | 0.86 | CNR2 (0.56) | CNR2CNR1PDE10ACYP1A2CYP2C19 | |
| SCHEMBL2736854 | 0.85 | CNR1 (0.48) | CNR2CNR1HDAC6PDE10AKMT2A | |
| SCHEMBL2736849 | 0.85 | CNR1 (0.48) | CNR2CNR1HDAC6PDE10ACYP1A2 | |
| SCHEMBL2736808 | 0.84 | CNR1 (0.48) | CNR2CNR1HDAC6PDE10ACYP1A2 | |
| SCHEMBL2736832 | 0.84 | CNR2 (0.58) | CNR2CNR1PDE10AKMT2ALMNA |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 6 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-8088924-B2 | Pyridone derivatives having a binding activity to the cannabinoid type 2 receptor | SHIONOGI & CO., LTD. (JP) | 2012-01-03 | — | — | US | disclosed |
| US-8088924-B2 | Pyridone derivatives having a binding activity to the cannabinoid type 2 receptor | SHIONOGI & CO., LTD. (JP) | 2012-01-03 | — | — | US | disclosed |
| US-20100081686-A1 | Pyridone derivatives having a binding activity to the cannabinoid type 2 recepter | TADA YUKIO | 2010-04-01 | — | — | US | disclosed |
| US-20100081686-A1 | Pyridone derivatives having a binding activity to the cannabinoid type 2 recepter | TADA YUKIO | 2010-04-01 | — | — | US | disclosed |
| US-7652141-B2 | Immunosuppressants, analgesics, antiinflammatory agents | SHIONOGI & CO., LTD. (JP) | 2010-01-26 | — | — | US | disclosed |
| US-7652141-B2 | Immunosuppressants, analgesics, antiinflammatory agents | SHIONOGI & CO., LTD. (JP) | 2010-01-26 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20100081686-A1 | Pyridone derivatives having a binding activity to the cannabinoid type 2 recepter | CNR2, CNR1, NPY2R | CNR2 1/4885CNR1 2/4885HDAC6 4752/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.